After five months of vaccination, the protection power is decreasing.

(New York News) Research data released by the American Disease Control and Prevention (CDC) shows that the two -year -old adolescents from 12 to 17 years old have been vaccinated by two doses.The medium disease caused by the Omikon variants of the Omiro variants has almost no protection.However, the third dose of vaccine can increase the large protection force. The authorities suggest that people 12 and above should be added with additional agents.

The New York Times reported that this study analyzed patients with coronary diseases 5 to 17 years old in the United States. From April last year to January this year, most of the emergency cases occurred.During the rapid spread of Omikon.The results showed that after about two months of vaccination for children 5 to 11, the effectiveness of the vaccine on preventing moderate diseases had dropped to 46%.

During Delta's raging period, Pfizer vaccine remained stable on the effectiveness of preventing moderate symptoms in preventing adolescents.However, after 150 days of vaccination, the effectiveness of the vaccine in preventing moderate diseases from 12 to 15 years old dropped to 38%, and the effectiveness of children aged 16 to 17 also dropped to 46%.

If you only look at the situation of Omikon, after completing the vaccination for more than 150 days, young people from 12 to 17 years old have almost lost their resistance to moderate diseases caused by Omikon.However, the third -time vaccine vaccine can restore effectiveness to 81%.

When the CDC relaxation of epidemic prevention guidelines and schools across the United States considering ending the mask order, this new study is particularly important for parents."We must also conduct more studies to see the results. But I think that as a parent, we should prepare for the possibility of children who may need to take another needle."

So far, the proportion of two -dose of crown diseases from 5 to 11 years old in the United States is less than 25%; more than half of young people aged 12 to 17 have completed the vaccination, and about 12%have hit the third third.Needle.CDC suggested that all Americans over 12 years old take over.Pfizer and Biontech are evaluating the benefits of the third dose vaccine to younger children.